The TCAP Gene Cardiomyopathy Dilated Type 1N Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE, designed to identify mutations in the TCAP gene, which are implicated in the development of Dilated Cardiomyopathy (DCM) type 1N. This condition is a form of heart disease that affects the heart's ability to pump blood efficiently, leading to enlargement of the heart's chambers and impaired cardiac function.
Given the genetic basis of DCM type 1N, identifying mutations in the TCAP gene can be crucial for early diagnosis, enabling timely management and intervention strategies for affected individuals. The test is particularly relevant for patients exhibiting symptoms of DCM or those with a family history of the condition, as it can provide essential insights into the genetic underpinnings of their cardiac issues.
Priced at 4400 AED, the test involves analyzing the patient's DNA to detect any genetic alterations in the TCAP gene that may predispose them to this specific type of cardiomyopathy. Conducted at DNA Labs UAE, a facility known for its state-of-the-art genetic testing services, this test represents a critical step towards personalized medicine in the field of cardiology, offering patients targeted and effective treatment plans based on their genetic makeup.
The ABCC9 Gene Cardiomyopathy Dilated Type 1O Genetic Test is a specialized diagnostic procedure offered by DNA Labs UAE, aimed at detecting mutations in the ABCC9 gene that are associated with dilated cardiomyopathy type 1O. Dilated cardiomyopathy (DCM) is a condition characterized by the enlargement and weakening of the heart's main pumping chamber, leading to decreased heart function and, potentially, heart failure. The ABCC9 gene plays a crucial role in the regulation of heart muscle contraction, and mutations in this gene can disrupt heart function, contributing to the development of DCM.
This genetic test involves collecting a DNA sample, typically through a blood draw or cheek swab, and analyzing the genetic material for specific mutations in the ABCC9 gene. Identifying these mutations can help in confirming a diagnosis of dilated cardiomyopathy type 1O, understanding the genetic cause of the condition, and guiding treatment decisions. Additionally, this information can be valuable for family planning and determining the risk of passing the condition on to future generations.
The cost of the ABCC9 Gene Cardiomyopathy Dilated Type 1O Genetic Test at DNA Labs UAE is 4400 AED. The test is conducted with high precision and confidentiality, ensuring that patients receive accurate and reliable results. By opting for this genetic test, individuals suspected of having or at risk for dilated cardiomyopathy can gain critical insights into their health, enabling them to make informed decisions regarding their medical care and lifestyle adjustments necessary to manage their condition effectively.
The "PLN Gene Cardiomyopathy Dilated Type 1P Genetic Test" is a specialized diagnostic tool offered by DNA Labs UAE, aimed at detecting mutations in the PLN gene, which are implicated in the development of Dilated Cardiomyopathy (DCM) type 1P. DCM is a condition characterized by the enlargement and weakening of the heart's ventricles, which can lead to heart failure and other serious cardiovascular complications. The PLN gene plays a crucial role in regulating calcium ions within heart muscle cells, and mutations in this gene can disrupt heart function, leading to the development of DCM.
This genetic test is designed to identify specific mutations in the PLN gene, providing vital information that can aid in the diagnosis, treatment planning, and risk assessment for affected individuals and their families. Early detection through genetic testing is key in managing the condition, allowing for timely interventions and lifestyle adjustments to mitigate the progression of the disease.
The test is conducted at DNA Labs UAE, a state-of-the-art facility known for its expertise in genetic diagnostics and personalized medicine. The cost of the test is 3200 AED, reflecting the comprehensive analysis and detailed insights it offers into the genetic underpinnings of Dilated Cardiomyopathy type 1P. By opting for this test, patients and healthcare providers can make informed decisions regarding the management of the condition, potentially improving the quality of life and outcomes for those affected.
The "ACTC1 Gene Cardiomyopathy Dilated Type 1R Genetic Test" is a specialized diagnostic procedure offered at DNA Labs UAE, designed to identify mutations in the ACTC1 gene that are associated with Dilated Cardiomyopathy Type 1R (DCM1R). Dilated cardiomyopathy is a condition characterized by the enlargement and weakening of the heart's main pumping chamber, which can lead to heart failure and other complications. The ACTC1 gene plays a crucial role in the structure and function of heart muscle cells, and mutations in this gene can disrupt heart muscle function, leading to DCM1R.
This genetic test involves collecting a DNA sample, typically through a blood draw or a cheek swab, and analyzing the genetic material for specific mutations in the ACTC1 gene. It is a powerful tool for early diagnosis, allowing for timely intervention and personalized treatment plans to manage symptoms and improve the quality of life for affected individuals.
The cost of the ACTC1 Gene Cardiomyopathy Dilated Type 1R Genetic Test at DNA Labs UAE is 4400 AED. This price reflects the specialized nature of the test, including the sophisticated technology and expertise required to accurately identify mutations in the ACTC1 gene. Early diagnosis through this genetic test can be crucial for individuals with a family history of dilated cardiomyopathy, as it provides valuable information for managing the condition and reducing the risk of complications.
The MYH7 Gene Cardiomyopathy Dilated Type 1S Genetic Test is a specialized diagnostic tool available at DNA Labs UAE, designed to detect mutations in the MYH7 gene, which are associated with dilated cardiomyopathy type 1S (DCM1S). Dilated cardiomyopathy is a condition characterized by the weakening of the heart muscle, leading to a decreased ability to pump blood effectively. The MYH7 gene encodes for the beta-myosin heavy chain, which is a critical component of the cardiac muscle fibers responsible for heart contractions.
Mutations in the MYH7 gene can disrupt the normal function of the heart muscle, contributing to the development of DCM1S. Early detection of these mutations through genetic testing can provide valuable information for the diagnosis, management, and treatment of affected individuals. It can also inform family members about their risk of developing the condition.
The test is priced at 4400 AED and involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in the laboratory for the presence of specific genetic mutations in the MYH7 gene. DNA Labs UAE offers this test with the expertise and technology necessary to ensure accurate and reliable results, providing crucial insights for patients and healthcare providers in the management of dilated cardiomyopathy.
The TMPO Gene Cardiomyopathy Dilated Type 1T Genetic Test is a specialized diagnostic tool designed to detect mutations in the TMPO gene, which are associated with dilated cardiomyopathy type 1T (DCM1T). Dilated cardiomyopathy is a condition characterized by the enlargement and weakening of the heart's main pumping chamber, which can lead to heart failure and other complications. The TMPO gene plays a critical role in the structural integrity and function of the heart muscle, and mutations in this gene can disrupt its normal function, leading to the development of DCM1T.
This genetic test is conducted at DNA Labs UAE, a leading facility in genetic diagnostics and research. The test involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in the laboratory for the presence of specific genetic mutations in the TMPO gene. The results of this test can provide valuable information for individuals with a family history of dilated cardiomyopathy or those experiencing symptoms related to heart muscle dysfunction.
The cost of the TMPO Gene Cardiomyopathy Dilated Type 1T Genetic Test is 4400 AED. This investment can be crucial for early detection and management of the condition, allowing individuals and their healthcare providers to make informed decisions regarding treatment and management strategies to mitigate the effects of the disease and improve quality of life.
The "PSEN1 Gene Cardiomyopathy Dilated Type 1U Genetic Test" is a specialized diagnostic tool designed to identify mutations in the PSEN1 gene, which are implicated in causing dilated cardiomyopathy of type 1U. Dilated cardiomyopathy (DCM) is a condition characterized by the enlargement and weakening of the heart's main pumping chamber, leading to decreased heart function and an increased risk of heart failure and arrhythmias. The PSEN1 gene plays a crucial role in the normal functioning of cardiac muscle cells, and mutations in this gene can disrupt heart muscle function, contributing to the development of DCM.
This genetic test is particularly valuable for individuals who have a family history of cardiomyopathy or have been diagnosed with unexplained dilated cardiomyopathy, as it can provide a definitive diagnosis of the genetic underpinnings of their condition. Identifying a PSEN1 mutation can also have important implications for the management and treatment of the disease, as well as for genetic counseling of the patient and their family members.
The test is offered by DNA Labs UAE, a leading provider of genetic testing services in the United Arab Emirates. The cost of the test is 4400 AED, reflecting the specialized nature of the analysis and the detailed, personalized information it provides. Conducted in a state-of-the-art laboratory by experienced geneticists and clinicians, the test involves collecting a DNA sample, typically through a blood draw, and analyzing it for the presence of mutations in the PSEN1 gene. Results from the test can help guide clinical decisions and offer patients a clearer understanding of their condition and its potential impact on their health and that of their family members.
The "PSEN2 Gene Cardiomyopathy Dilated Type 1V Genetic Test" is a specialized diagnostic tool used to detect mutations in the PSEN2 gene, which are implicated in the development of Dilated Cardiomyopathy Type 1V. This condition is a form of heart disease characterized by the dilation and impaired contraction of the left ventricle or both ventricles, which can lead to heart failure and other serious complications. The test is crucial for individuals with a family history of cardiomyopathy or those exhibiting symptoms, as early detection can significantly influence management and treatment strategies.
Performed at DNA Labs UAE, a leading facility in genetic testing, the test offers a comprehensive analysis of the PSEN2 gene to identify any genetic abnormalities that may predispose an individual to this type of cardiomyopathy. By utilizing advanced genetic sequencing techniques, DNA Labs UAE ensures accurate and reliable results, providing essential information for personalized patient care.
The cost of the PSEN2 Gene Cardiomyopathy Dilated Type 1V Genetic Test is set at 4400 AED. This investment covers the sophisticated processes involved in the genetic analysis, from sample collection to data interpretation, delivered by highly skilled professionals in the field of genetic diagnostics. For those at risk, this test represents a critical step towards understanding their genetic health, enabling proactive measures to manage or mitigate the impact of Dilated Cardiomyopathy Type 1V.
The "VCL Gene Cardiomyopathy Dilated Type 1W Genetic Test" is a specialized diagnostic tool available at DNA Labs UAE, designed to identify mutations in the VCL gene, which are associated with dilated cardiomyopathy type 1W (DCM1W). Dilated cardiomyopathy is a condition characterized by the enlargement and weakening of the heart's ventricles, leading to reduced heart function and potentially serious health complications. The VCL gene plays a crucial role in the structure and function of heart muscle cells, and mutations in this gene can disrupt heart muscle function, contributing to the development of DCM1W.
This genetic test is essential for individuals with a family history of dilated cardiomyopathy or those showing symptoms of the condition, as early detection can significantly influence management and treatment strategies. Conducted at DNA Labs UAE, a leading facility in genetic diagnostics, the test ensures accuracy and reliability in detecting VCL gene mutations.
The cost of the VCL Gene Cardiomyopathy Dilated Type 1W Genetic Test is set at 4400 AED. While the price may seem high, the test offers invaluable insights into an individual's genetic predisposition to this form of cardiomyopathy, enabling targeted interventions and personalized care plans to mitigate health risks associated with the condition.
The FKTN Gene Cardiomyopathy Dilated Type 1X Genetic Test is a specialized diagnostic tool used to identify mutations in the FKTN gene, which are linked to the development of dilated cardiomyopathy type 1X (DCM1X). This condition is a form of heart disease characterized by the enlargement and weakening of the heart's main pumping chamber, leading to decreased heart function and potentially severe cardiac symptoms, including heart failure.
Performed at DNA Labs UAE, this genetic test involves collecting a DNA sample, typically through a blood draw or a cheek swab, and analyzing it for specific genetic alterations in the FKTN gene. The presence of these mutations can confirm the diagnosis of DCM1X, allowing for personalized treatment plans and management strategies to be developed for affected individuals.
The cost of the FKTN Gene Cardiomyopathy Dilated Type 1X Genetic Test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis required to detect the genetic variations associated with this condition, providing crucial information for patients and their families regarding the prognosis, potential treatment options, and the likelihood of passing the condition on to future generations.
